In this slide show we highlight some of the top news on gynecologic cancers in 2017, including studies on surgery for cervical and ovarian cancer, the FDA approval of niraparib, and more.
Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis
Learn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.
Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer
The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.
Nivolumab ± Ipilimumab Yields Durable Responses in Cervical Cancer
The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.
Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances
Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers
The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.
Rintatolimod Combo Yields Clinical Benefit in Recurrent Ovarian Cancer
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.